New shot aims to tame rare liver virus
NCT ID NCT06505928
First seen Dec 23, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tests a new drug called hepalatide (L47) in 90 adults with chronic hepatitis D, a serious liver infection. Participants receive either a low or high dose of the drug daily for 48 weeks, or wait for treatment. The goal is to see if the drug can lower the virus level and bring liver enzymes back to normal.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Center for Communicable Diseases
Ulaanbaatar, Mongolia
-
National cancer canter of Monglia
Ulaanbaatar, 13370, Mongolia
Conditions
Explore the condition pages connected to this study.